Our mission is simple—develop a drug that works. We recognize that there are no treatments for peripheral neuropathy today. We strive to impact the lives of today’s patients heavily burdened by this disease.
“We have found what appears to be the first disease-modifying treatment for neuropathy. We are the first company developing a drug which appears to be regenerating peripheral nerves, which is pretty amazing.”
We are impatient. We are exploiting every strategy, mechanism and regulation to accelerate approval of our drugs, including recycling an active ingredient in use for nearly 40 years in Europe and Asia. Currently, we are preparing to start our Phase 3 global study for diabetic peripheral neuropathy. Our goal is to get drug approval in the US as soon as possible, and possibly sooner in other countries. By focusing on patient impact rather than the bottom line, we believe we’re creating a new sustainable model for pharma companies based on patient need, not just money.
